HER2, PD-1, and receptor tyrosine kinases (RTKs) are the most common molecular targets for both branded and pipeline drugs. However, the treatment landscape remains dominated by non-targeted chemotherapies, with most targeted agents confined to one or two treatment settings, where they are typically administered alongside chemotherapy. 

No targeted therapies exist for locoregional disease, although various PD-1 inhibitors are under investigation. 

This Datamonitor Healthcare report contains a Disease Analysis module.